Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Linda Manoogian Fingerle to its board.

Abingworth Management, of London, appointed Michelle Doig an adviser for funding and refinancing its portfolio companies.

Acacia Research Corp., of Newport Beach, Calif., appointed Jennifer Hart vice president of business development.

Adventrx Pharmaceuticals, of San Diego, appointed Mark Bagnall to its board and Mark Cantwell director of preclinical programs.

Agensys Inc., of Santa Monica, Calif., elected Richard Brewer to its board.

Alexion Pharmaceuticals Inc., of Cheshire, Conn., appointed Carsten Boess vice president and chief financial officer.

Apax Partners, of Menlo Park, Calif., appointed Carol Olson a venture partner focused on biotechnology.

Kane Biotech Inc., of Winnipeg, Manitoba, appointed Geoffrey Grant to its board.

MDS Pharma Services, of Montreal, named Paul Chamberlain, Guy Chamberland, Ian Dews, Malle Jurima-Romet, Bruce Morimoto and Douglas Wight program directors for drug development. It also named Michel Roy a program manager.

Medicure Inc., of Winnipeg, Manitoba, appointed Gerald McDole to its board.

Merck KgaA, of Darmstadt, Germany, named Juergen Knackmuss company spokesman, in addition to his duty as director of public affairs.

Molecular Imaging Corp., of San Diego, named Dennis Mulroy chief financial officer.

NeoGenomics Inc., of Fort Myers, Fla., appointed Thomas White CEO.

Neurobiological Technologies Inc., of Richmond, Calif., appointed F. Van Kasper to its board and chairman of the company's audit committee.

Neurochem Inc., of Montreal, appointed Christine Lennon vice president of business development and Judith Paquin vice president of human resources.

Neurogen Corp., of Branford, Conn., appointed Lai Foon Lee vice president of finance.

NeurogesX Inc., of San Carlos, Calif., appointed Michael Markels senior director of sales and marketing.

NitroMed Inc., of Bedford, Mass., appointed Joseph Loscalzo to its board.

Osiris Therapeutics Inc., of Baltimore, elected Mehmet Oz to its board.

PDI Inc., of Upper Saddle River, N.J., said Alan Rubino was appointed executive vice president and general manager of the sales team business.

ProCyte Corp., of Redmond, Wash., appointed Christopher Gabanski director of sales.

Rigel Pharmaceuticals Inc., of South San Francisco, appointed Hollings Renton to its board.

Salix Pharmaceuticals Inc., of Raleigh, N.C., appointed William Keane to its board.

Sopherion Therapeutics Inc., of New Haven, Conn., appointed Gunnar Casserstedt chief financial officer and vice president of finance.

Spectrum Pharmaceuticals Inc., of Irvine, Calif., appointed Anthony Maida to its board and its audit committee.

Targacept Inc., of Winston-Salem, N.C., added Errol De Souza to its board.

Thios Pharmaceuticals Inc., of Emeryville, Calif., appointed Stephen Harrison vice president of research.

Transkaryotic Therapies Inc., of Cambridge, Mass., named Paul McCabe country manager in Canada. He will oversee Replagal sales and marketing initiatives.

Tripos Inc., of St. Louis, promoted Dieter Schmidt-Base to senior vice president of worldwide sales.

Ventaira Pharmaceuticals, of Columbus, Ohio, formerly BattellePharma, appointed Mark Kontny senior vice president of research and development and chief scientist.

Vion Pharmaceuticals Inc., of New Haven, Conn., appointed Howard Johnson president.

VIRxSYS Corp., of Gaithersburg, Md., appointed John Phair to its board.

Xcyte Therapies Inc., of Seattle, appointed Robert Kirkman chief business officer and vice president.

Zila Inc., of Phoenix, Ariz., appointed Andrew Stevens chief financial officer.